Chemistry:SEP-4199

From HandWiki

SEP-4199, also known as non-racemic amisulpride, is a non-racemic form of amisulpride which is under development for the treatment of bipolar depression.[1][2][3] It is taken by mouth.[1]

It was developed to have higher binding affinity for the serotonin 5-HT7 receptor and lower affinity for the dopamine D2 receptor compared to conventional racemic amisulpride.[1][3][4][5] It contains the (R)- and (S)-enantiomers of amisulpride (aramisulpride and esamisulpride) in an 85:15 ratio rather than a 50:50 ratio.[3] The modification is hoped to give the compound improved effectiveness and fewer side effects.[3][6]

If approved, it would be the first form of amisulpride approved in the United States for psychiatric indications.[5] It is in phase 3 clinical trials for bipolar depression as of December 2023.[1][7] Its development was reported to have been discontinued in certain countries including the United States and Japan in November and December 2023.[1] Sources are conflicting on whether it remains in development.[1][2]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "SEP 4199". 20 December 2023. https://adisinsight.springer.com/drugs/800052192. 
  2. ↑ 2.0 2.1 "Delving into the Latest Updates on Aramisulpride/Esamisulpride with Synapse". 15 October 2024. https://synapse.patsnap.com/drug/946c3f3c25ab44f495f0fe9a4ce9b559. 
  3. ↑ 3.0 3.1 3.2 3.3 "A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia". Expert Rev Clin Pharmacol 16 (11): 1085–1092. 2023. doi:10.1080/17512433.2023.2274538. PMID 37864424. 
  4. ↑ Hopkins, Seth C.; Wilkinson, Scott; Corriveau, Taryn J.; Nishikawa, Hiroyuki; Nakamichi, Keiko; Loebel, Antony; Koblan, Kenneth S. (2021). "Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders". Clinical Pharmacology & Therapeutics 110 (3): 808–815. doi:10.1002/cpt.2282. PMID 33961287. 
  5. ↑ 5.0 5.1 Loebel, Antony; Koblan, Kenneth S.; Tsai, Joyce; Deng, Ling; Fava, Maurizio; Kent, Justine; Hopkins, Seth C. (1 January 2022). "A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression". Journal of Affective Disorders 296: 549–558. doi:10.1016/j.jad.2021.09.109. ISSN 0165-0327. PMID 34614447. 
  6. ↑ Wu, Jie; Kwan, Angela TH; Rhee, Taeho Greg; Ho, Roger; d’Andrea, Giacomo; Martinotti, Giovanni; Teopiz, Kayla M; Ceban, Felicia et al. (21 October 2023). "A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia" (in en). Expert Review of Clinical Pharmacology 16 (11): 1085–1092. doi:10.1080/17512433.2023.2274538. ISSN 1751-2433. PMID 37864424. https://www.tandfonline.com/doi/abs/10.1080/17512433.2023.2274538. 
  7. ↑ "Sumitomo, Otsuka's Schizophrenia Candidate Fails Phase III Trials". 31 July 2023. https://www.biospace.com/article/sumitomo-otsuka-s-schizophrenia-candidate-fails-phase-iii-trials-/. "Ulotaront failed to meet primary endpoints in two studies. [...] Ulotaront is also in Phase II/III clinical studies as an adjunctive treatment for major depressive disorder as well as generalized anxiety disorder. Another asset from the deal, SEP-4199, is in a Phase III study for bipolar I depression." 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:SEP-4199&oldid=4244479"